Alcohol

More documents

Recommendations

Info

Baclofen blunts Amygdala Connectivity during 500 msec “SEEN” Cocaine Cues Placebo Baclofen Second half of the task [Drug 2; placebo n = 9; baclofen n =10]
Novel Treatment arising from animal models Naltrexone for alcoholism - alcohol activates E.O. GABA enhancers (e.g. Vigabatrin, Topiramate) inhibit VTA-N.Ac DA activation Cocaine, alcohol NK-1 antagonist, in clinical trials Varenicline for nicotine, alcohol, cocaine Potential new candidate N-acetyl cysteine glutamate depletion in cocaine addicts cysteine-glut. Exchange reversal cocaine reinstatement blocked
Page 1 and 2: The Path to Genomic Medicine For Ad
Page 3 and 4: Use Use Use Use Use Abuse (declarat
Page 5 and 6: Possible Changes • Addiction inst
Page 7 and 8: Addiction: Loss of control • Jean
Page 9 and 10: Possible Families of Risk Factors
Page 11 and 12: Response • Genetically influenced
Page 13 and 14: Drugs of Abuse all Activate Reward
Page 15 and 16: Effects of Drugs on Dopamine Levels
Page 17 and 18: Relationship between Cue-Induced De
Page 19: “Unseen” Reward Cues activate a
Page 22 and 23: Alcoholism: FDA Approved Medication
Page 24 and 25: Alcohol - Beverage Condition Cingul
Page 28 and 29: Alcohol reward Sedating drug, facil
Page 30 and 31: True Translational Story: Naltrexon
Page 32: Naltrexone decreases Alcohol prefer
Page 38 and 39: Ethanol Responses Saline 80 70 60 5
Page 40 and 41: Naltrexone Concurrently Antagonizes
Page 42 and 43: Brain Reward System Nucleus Accumbe
Page 44 and 45: Dopamine Opioid Antagonism Dopamine
Page 46 and 47: Propose an RCT of an opiate antagon
Page 48 and 49: Naltrexone Affinity at Opioid Recep
Page 50 and 51: Receptor Blockade with Naltrexone i
Page 52 and 53: Post-Docs Tom Aronson, MD Joseph Vo
Page 54 and 55: Pharmacological Treatments for Alco
Page 56 and 57: Days Drinking 1.0 0.8 0.6 0.4 0.2 0
Page 58 and 59: Alcohol Relapse A. coming to treatm
Page 60 and 61: Rates of Never Relapsing According
Page 62 and 63: Blood Alcohol levels (g/dl) 0.1 0.0
Page 64 and 65: Studies supporting efficacy Studies
Page 66 and 67: Baseline Craving Scores % Days Heav
Page 68 and 69: Baseline b-Endorphin Levels in Low-
Page 70 and 71: Key effect: Sensitivity of Endogeno
Page 72 and 73: BAES Stimulation Scores Among FH+ a
Page 74 and 75: Human Mu Opioid Receptor Gene PROMO
Page 76 and 77:
Alcohol effects by genotype 50 45 4
Page 78 and 79:
Lotsch et al, 2006
Page 80 and 81:
Ethnicity & A118G Allele Frequency
Page 82 and 83:
Subjective “high” in Naltrexone
Page 84 and 85:
OPRM1 A118G and Alcoholism Bart et
Page 86 and 87:
COMBINE Study • N = 1383; 9 rando
Page 88 and 89:
Rhesus model Ortholog of A118G alle
Page 90 and 91:
Results: Heavy Drinking Days 30 75
Page 92 and 93:
Endophenotype Endorphin Dependent A
Page 94 and 95:
Medications • Nicotine Nicotine p
Page 96 and 97:
FOR MORE INFORMATION http://www.med
show all

Alcohol

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?